Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-244.83	-219.71	35.38	-25.69
Depreciation & Amortization	0.94	0.84	1.29	1.25
Loss (Gain) From Sale of Assets	0.48	0.48	-0.15	-
Asset Writedown & Restructuring Costs	0.71	0.71	-	-
Loss (Gain) From Sale of Investments	-	-0.08	-0.38	0.06
Stock-Based Compensation	18.86	22.52	11.19	7.72
Other Operating Activities	200.43	139.1	-18.59	4.47
Change in Accounts Receivable	0.96	0.91	0.16	-2.69
Change in Accounts Payable	0.11	2.83	0.09	-0.22
Change in Unearned Revenue	-8.12	5.26	-64.71	-45.5
Change in Income Taxes	-	-	-0.6	0.6
Change in Other Net Operating Assets	-9.5	-4.03	4.68	-0.39
Operating Cash Flow	-39.96	-51.16	-31.63	-60.38
Capital Expenditures	-8.45	-0.21	-1.2	-1.09
Cash Acquisitions	6.56	6.56	-	-
Investment in Securities	-	28.25	-13.8	-16.06
Investing Cash Flow	-1.89	34.61	-15	-17.14
Long-Term Debt Repaid	-	-27.46	-	-
Net Debt Issued (Repaid)	-	-27.46	-	-
Issuance of Common Stock	127.65	0.23	39.33	52.9
Other Financing Activities	-6.17	-6.17	-0.11	-
Financing Cash Flow	181.73	-13.15	39.22	52.9
Foreign Exchange Rate Adjustments	0.01	-0.05	0.02	-0
Net Cash Flow	139.89	-29.75	-7.4	-24.63
Free Cash Flow	-48.41	-51.37	-32.83	-61.47
Free Cash Flow Margin	-100.98%	-197.53%	-29.64%	-72.25%
Free Cash Flow Per Share	-3.95	-9.93	-6.75	-16.13
Cash Interest Paid	-	1.85	2.25	2
Levered Free Cash Flow	-2.93	28.9	22.24	-
Unlevered Free Cash Flow	-2.93	30.67	24.13	-
Change in Net Working Capital	-7.91	-50.77	-3.77	-

Source: S&P Capital IQ. Standard template. Financial Sources.